Impact of zervimesine on the neuroinflammatory biomarker GFAP and related proteomic molecular correlates in plasma of participants from a phase 2 clinical trial in Alzheimer's disease. The gene discussed is GFAP; the disease is early-onset autosomal dominant Alzheimer disease.